La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Longeveron Gestion

Gestion contrôle des critères 0/4

Le PDG Longeveron's est Mohamed Wa'el Hashad, nommé en Mar2023, a un mandat de 1.42 ans. La rémunération annuelle totale est $ 1.66M, composée du salaire de 25.9% et des bonus 74.1%, y compris les actions et options de la société. détient directement 0.14% des actions de la société, d'une valeur de $ 46.10K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.1 ans et 2.2 ans.

Informations clés

Mohamed Wa'el Hashad

Directeur général

US$1.7m

Rémunération totale

Pourcentage du salaire du PDG	25.9%
Durée du mandat du directeur général	1.6yrs
Propriété du PDG	0.6%
Durée moyenne d'occupation des postes de direction	1.2yrs
Durée moyenne du mandat des membres du conseil d'administration	2.3yrs

Mises à jour récentes de la gestion

Recent updates

Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference

Jul 07

Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market

May 06

Analyse de la rémunération des PDG

Comment la rémunération de Mohamed Wa'el Hashad a-t-elle évolué par rapport aux bénéfices de Longeveron?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	US$2m	US$431k	-US$22m

Rémunération vs marché: La rémunération totale de Mohamed Wa'el ($USD 1.66M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Mohamed Wa'el avec les performances de l'entreprise.

PDG

Mohamed Wa'el Hashad (62 yo)

1.6yrs

Titularisation

US$1,662,854

Compensation

Mr. Mohamed Wa'el Ahmed Hashad, M.B.A. has been Chief Executive Officer at Longeveron Inc. since February 2023 and also has been its Director since June 09, 2023. Mr. Hashad has been Independent Director a...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Joshua Hare	Co-Founder	10.7yrs	US$87.13k	8.29% $ 2.4m
Mohamed Wa'el Hashad	CEO & Director	1.6yrs	US$1.66m	0.63% $ 179.8k
Lisa Locklear	CFO & Treasurer	1.2yrs	US$604.67k	1.14% $ 325.6k
Paul Lehr	International Executive Director	no data	US$554.06k	2.01% $ 574.5k
Dan Gincel	Senior Vice President of Strategic Collaborations & Scientific Affairs	3.3yrs	pas de données	pas de données
Nataliya Agafonova	Chief Medical Officer	1.2yrs	pas de données	1.14% $ 324.6k
Lisa McClain-Moss	Vice President of Manufacturing	no data	pas de données	pas de données
Brian Rash	VP of Research & Discovery	no data	pas de données	pas de données
Elly Ryu	VP & Corporate Controller	less than a year	pas de données	pas de données
Michael Mannarino	VP & Corporate Controller	less than a year	pas de données	pas de données

1.2yrs

Durée moyenne de l'emploi

55.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de LGVN n'est pas considérée comme expérimentée (ancienneté moyenne 1.1 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Joshua Hare	Co-Founder	10.7yrs	US$87.13k	8.29% $ 2.4m
Mohamed Wa'el Hashad	CEO & Director	1.3yrs	US$1.66m	0.63% $ 179.8k
Roger Hajjar	Independent Director	less than a year	pas de données	pas de données
Richard Kender	Independent Director	less than a year	pas de données	pas de données
Joe G. Garcia	Member of Scientific Advisory Board	no data	pas de données	pas de données
Khoso Baluch	Independent Director	1.3yrs	US$47.78k	0.10% $ 29.6k
Jeremy Walston	Member of Scientific Advisory Board	no data	pas de données	pas de données
Elena Volpi	Member of Scientific Advisory Board	no data	pas de données	pas de données
Hidenori Arai	Member of Scientific Advisory Board	no data	pas de données	pas de données
Neil Hare	Director	9yrs	US$52.13k	2.13% $ 607.4k
Rock Soffer	Director	4.5yrs	US$55.63k	1.45% $ 415.0k
Ursula Ungaro	Independent Director	3.3yrs	US$62.63k	0.0035% $ 994.4

2.3yrs

Durée moyenne de l'emploi

61.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de LGVN ne sont pas considérés comme expérimentés (ancienneté moyenne 2.2 ans), ce qui suggère un nouveau conseil d'administration.

Longeveron Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Longeveron Inc. Elects Neha Motwani to Its Board of Directors

Longeveron Inc. Appoints Roger Hajjar to Board of Directors

Longeveron Inc., Annual General Meeting, Jul 02, 2024

Less than half of directors are independent

Longeveron Inc. Announces Board Changes

Director exercised options to buy US$70k worth of stock.

Recent updates

Longeveron Inc. Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS)

Consensus estimates of losses per share improve by 12%

Price target decreased by 31% to US$8.32

Consensus revenue estimates fall by 14%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Longeveron Inc. to Report Q2, 2024 Results on Aug 14, 2024

Consensus revenue estimates increase by 21%

Price target decreased by 10% to US$11.32

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

Consensus EPS estimates upgraded to US$3.42 loss

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $9.000005 million.

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

Longeveron Inc. Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Longeveron Inc. Elects Neha Motwani to Its Board of Directors

Longeveron Inc. Appoints Roger Hajjar to Board of Directors

Price target decreased by 12% to US$12.30

Consensus EPS estimates upgraded to US$3.91 loss

Longeveron Inc., Annual General Meeting, Jul 02, 2024

Consensus revenue estimates increase by 931%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Longeveron Inc. Announces Board Changes

Longeveron Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus EPS estimates upgraded to US$5.85 loss

Price target decreased by 48% to US$37.50

New major risk - Share price stability

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $5.248428 million.

New major risk - Shareholder dilution

New major risk - Market cap size

Longeveron Announces 1-For-10 Reverse Stock Split to Regain Compliance

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Full year 2023 earnings: EPS misses analyst expectations

Longeveron Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $2.365 million.

Longeveron Inc. has filed a Follow-on Equity Offering in the amount of $2.195588 million.

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’S Disease

Long-Term Survival Data from Longeveron’s Elpis 1 Trial Presented At the 2023 Scientific Sessions of the American Heart Association

Longeveron Inc. to Report Q3, 2023 Results on Nov 10, 2023

Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from Clear MIND Phase 2a Clinical Trial of Lomecel-B™? for the Treatment of Mild Alzheimer's

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%

Longeveron Inc. Announces Positive Top-Line Results for Lomecel-B in Its Clear Mind Phase 2A Clinical Trial in the Treatment of Mild Alzheimer’s Disease

Director exercised options to buy US$70k worth of stock.

New major risk - Revenue size

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q2, 2023 Results on Aug 11, 2023

Longeveron Inc. Announces the Appointment of Lisa Locklear as Chief Financial Officer, Effective July 31, 2023

Longeveron Inc. Appoints Nataliya Agafonova M.D. as Chief Medical Officer

High number of new directors

Longeveron Inc. Approves Bord Appointments

Longeveron Inc. Announces Resignation of James Clavijo as CFO

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: US$0.90 loss per share (vs US$0.90 loss in FY 2021)

Price target decreased to US$15.50

Longeveron Provides Corporate Update

Consensus forecasts updated

Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Longeveron Inc. Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’S Disease

Longeveron Inc. to Report Q3, 2022 Results on Nov 14, 2022

Longeveron Inc.: A New Approach To Treat Alzheimer's

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron's Lomecel-B(TM) Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants